MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Endothelial-to-Mesenchymal Transition

  • Home
  • Endothelial-to-Mesenchymal Transition
RUNX1-Driven Endothelial-to-Mesenchymal Transition: A Novel Mechanistic Link and Therapeutic Target in LMNA Cardiomyopathy
Posted inCardiology news

RUNX1-Driven Endothelial-to-Mesenchymal Transition: A Novel Mechanistic Link and Therapeutic Target in LMNA Cardiomyopathy

Posted by By MedXY 08/21/2026
This study identifies RUNX1-mediated endothelial-to-mesenchymal transition as a key driver of myocardial fibrosis and remodeling in LMNA cardiomyopathy, highlighting potential therapeutic avenues targeting endothelial RUNX1 signaling.
Read More
Posted inGastroenterology news

Endothelial-to-Mesenchymal Transition: Unlocking New Therapeutic Avenues for Portal Vein Thrombosis in Cirrhosis

Posted by By Zhang Paul 07/23/2026
Highlight Portal vein thrombosis (PVT) in cirrhosis involves unique structural and cellular changes, including eccentric…
Read More
  • Clinical Utility of a 30% Reduction in VCTE-Derived Liver Stiffness Measurement for Identifying Histologic Improvement in Metabolic Dysfunction-Associated Steatohepatitis
  • Reevaluating Colorectal Cancer Surveillance in Inflammatory Bowel Disease: The Role of Family History Beyond Early-Onset Cases
  • Ticagrelor-Aspirin Dual Therapy After Thrombolysis in Moderate Ischemic Stroke: Insights from Infarct Patterns in the TAPIS Trial
  • Cilostazol Therapy in Intracerebral Hemorrhage: Enhancing Dural Lymphatic Function for Neuroprotection
  • CSF Biomarkers as Indicators of Disease Severity in Probable Cerebral Amyloid Angiopathy: Insights Beyond MRI
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top